Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-05-24
2010-12-28
Goddard, Laura B (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100
Reexamination Certificate
active
07858331
ABSTRACT:
Disclosed herein are methods and compositions for the treatment of cancer. In particular, the present invention discloses inhibitors of the Fanconi anemia pathway and methods using same. Such inhibitors are useful in inhibiting DNA damage repair and can be useful, for example, in the treatment of cancer.
REFERENCES:
patent: 3854480 (1974-12-01), Zaffaroni
patent: 4452775 (1984-06-01), Kent
patent: 5239660 (1993-08-01), Ooi
patent: 7459287 (2008-12-01), D'Andrea
patent: 2003/0093819 (2003-05-01), D'Andrea et al.
patent: 2003/0188326 (2003-10-01), D'Andrea et al.
patent: 2004/0002492 (2004-01-01), Murray Smith et al.
patent: WO-0053169 (2000-09-01), None
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Zips et al. (2005, In Vivo, 19:1-7).
Shimamura et al (Blood, Dec. 2002, 100:4649-4654).
Ferrer et al (Clinical Lung Cancer, Jan. 2005, 6:250-254).
Grover et al., “Cisplatin and the Sensitive Cell”, Nature Medicine, vol. 9, No. 5, p. 513-514 (2003).
Andreassen et al., “ATR couples FANCD2 monoubiquitination to the DNA-damage response”,Genes Dev., 18:1958-1963 (2004).
Cheng et al., “Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions”,Anticancer Res., 21:2895-2900 (2001).
Chirnomas et al., “Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway”,Mol. Cancer Ther., 5(4):952-961 (2006).
D'Andrea et al., “The FanconiAnaemia/BRCA Pathway”,Nat. Rev. Cancer, 3:23-34 (2003).
Digweed et al., “Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia”,Carcinogenesis, 23(7):1121-1126 (2002).
Dunn, F.B., “Heat shock protein inhibitor shows antitumor activity”,J. Natl. Cancer Inst., 94:1194-1195 (2002).
Egan et al., “Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects”,Science, 304:600-602 (2004).
Garcia-Higuera et al., “Interaction of the Fanconi Anemia proteins and BRCA1 in a common pathway”,Mol. Cell., 7:249-262 (2001).
Gregory et al., “Regulation of the Fanconi anemia pathway by monoubiquination”,Seminars in Cancer Biology, 13:77-82 (2003).
Haining et al., “Rapid assessment of Fanconi pathway function: A new diagnostic approach to Fanconi Anemia”,Blood, 96(11):977 (Abstract Only).
Holzel et al., “FANCD2 protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anaemia”,J. Pathology, 201:198-203 (2003).
Inagaki et al., “N-(2-Aminoethyl)-5-isoquinolinesulfonamide, a newly synthesized protein kinase inhibitor, functions as a ligand in affinity chromatography. Purification of Ca2+-activated, phospholipid-dependent and other protein kinases”,J. Biol. Chem., 260(5):2922-2925 (1985).
Ito et al., “A potent inhibitor of protein kinase C inhibits natural killer activity”,Int. J. Immunopharmacol., 10(3):211-216 (1988).
Kau et al., “A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells”,Cancer Cell., 4:463-476 (2003).
Lensch et al., “Acquired FANCA dysfunction and cytogenic instability in adult acute myelogenous leukemia”,Blood, 102(1):7-16 (2003).
Nakanishi et al., “Interaction of FANCD2 and NBS1 in the DNA damage response”,Nat. Cell Biol., 4:913-920 (2002).
Sausville et al., “Inhibition of CDKs as a therapeutic modality”,Ann. N. Y. Acad. Sci., 910:207-221 (2000).
Schnur et al., “Inhibition of the oncogene product p185erbB-2in vitro and in vivo by geldanamycin and di hydrogeldanamycin derivatives”,J. Med. Chem., 38:3806-3812 (1995).
Schultz et al., “Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, andin vitroantitumor activity”,J. Med. Chem., 42:2909-2919 (1999).
Taniguchi et al., “Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways”,Cell, 109:459-472 (2002).
Taniguchi et al., “Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors”,Nat. Med., 9(5):568-574 (2003).
Taniguchi et al., “DNA damage-induced association of the Fanconi Anemia protein, FANCD2, with BRCA1 nuclear foci”,Blood, 96(11):2402 (Abstract Only), 2000.
Taniguchi et al., “Molecular pathogenesis of Fanconi anemia: recent progress”,Blood, 107(11):4223-4233 (2006).
Timmers et al., “Positional Cloning of a Novel Fanconi Anemia Gene,FANCD2”, Mol. Cell., 7:241-248 (2001).
Yang et al., “P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin”,Oncol. Res., 7(12):619-624 (1995).
D'Andrea Alan D.
Taniguchi Toshiyasu
Dana Farber Cancer Institute, Inc.
Elrifi Ivor R.
Goddard Laura B
Kozakiewicz Cynthia A.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Compositions and methods for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4217397